Thromboelastography is a dynamic indicator of blood coagulation, including fibrinogen and platelet dysfunction. It is mainly used to evaluate thrombophilia or platelet dysfunction, as well as the risk of bleeding. It is generally used in pregnant women, patients with pulmonary embolism and severe thrombotic or coronary artery disease, and in patients with liver dysfunction to assess bleeding risk. Thromboelastography can also guide the application of antiplatelet drugs, assess whether the patient’s platelet function is impaired, and evaluate the bleeding risk of the application of antiplatelet drugs such as aspirin and Tegretol. For patients with unexplained recurrent thrombophilia, or in the presence of coagulation factor abnormalities, thromboelastography also has a diagnostic role. For patients with cardiovascular and cerebrovascular diseases or after stenting, oral “double antibiotic”, thromboelastography can monitor the strength of antiplatelet aggregation; AA>50%, ADP>30% indicates that the drug is effective; both more than 70% indicates that the risk of bleeding is increased; both <30% indicates that the drug is not effective, and the risk of thrombotic events is increased.